RESEARCH TRIANGLE PARK, N.C. — AlphaVax, a vaccine company, has received a U.S. patent that covers its preparation process for the manufacturing of so-called alphavaccines.

The process enables the inclusion of antigens in vaccines that target infectious disease, cancer, and can act as a biodefense.

“These key enabling process steps allow AlphaVax to meet the scale-up and regulatory requirements for commercialization and reflect our emphasis on downstream process and product development,” said Chief Scientific Officer Jonathan Smith in a statement. “We continue to build a body of know-how and patents surrounding the alphavaccine technology and the issuance of this patent is a keystone in the company’s proprietary strategy.”